Multi-Modality Breast Biopsy System Garners FDA Clearance

The Food and Drug Administration has granted 510(k) clearance for the EnCor EnCompass Breast Biopsy and Tissue Removal System (BD), which may facilitate streamlined breast biopsy procedures across different breast imaging modalities.

In addition to multi-modality use with the EnCor EnCompass Biopsy System, BD said the system offers high and low vacuum strengths and enhanced sampling capability to enable access to lesions in different areas of the breast.

Other key attributes of the EnCor EnCompass Biopsy System include an echogenic cutting cannula as well as 7G, 10G and 12G probes that can help address a variety of lesion types and locations, according to BD.

“Our goal is always to provide the best possible care for patients while maintaining efficiency, accuracy, and safety," said Shadi Aminololama-Shakeri, M.D., the chief of breast radiology at the University of California-Davis. “The EnCor EnCompass Biopsy System combines multi-modality capability and enhanced control into one platform that supports intraprocedural customization and helps streamline the biopsy process.”